Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 1/2016

01-02-2016 | HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection

Authors: Michael L. Freeman, Michael M. Lederman, Sara Gianella

Published in: Current HIV/AIDS Reports | Issue 1/2016

Login to get access

Abstract

In the current era of combination antiretroviral therapy (ART), human immunodeficiency virus (HIV)-infected individuals are living longer and healthier lives. Nevertheless, HIV-infected persons are at greater risk for age-related disorders, which have been linked to residual immune dysfunction and inflammation. HIV-infected individuals are almost universally co-infected with cytomegalovirus (CMV) and both viruses are associated with inflammation-related morbidities. Therefore, a detailed investigation of the relationship between CMV and aging-related morbidities emerging during chronic HIV infection is warranted. Here, we review the literature on how CMV co-infection affects HIV infection and host immunity and we discuss the gaps in our knowledge that need elucidation.
Literature
1.
Palella Jr FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34.PubMedCrossRef
2.
3.
4.
Unemori P, Leslie KS, Hunt PW, et al. Immunosenescence is associated with presence of Kaposi’s sarcoma in antiretroviral treated HIV infection. AIDS. 2013;27:1735–42.PubMedPubMedCentralCrossRef
5.
Appay V, Fastenackels S, Katlama C, et al. Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. AIDS. 2011;25:1813–22.PubMedCrossRef
6.
Durier N, Ananworanich J, Apornpong T, et al. Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: prevalence and associated mortality. Clin Infect Dis. 2013;57:147–55.PubMedCrossRef
7.
Fishman JA. Overview: cytomegalovirus and the herpesviruses in transplantation. Am J Trans Off J Am Soc Trans Am Soc Trans Surg. 2013;13:1–8.CrossRef
8.
Richman DD. Clinical Virology. ASM Press; 3 edition (January 1, 2009). 1408 pp.
9.
Gianella S, Massanella M, Wertheim JO, Smith DM. The sordid affair between human herpesvirus and human immunodeficiency virus. J Infect Dis. 2015;212(6):845–52.
10.
Sinclair J, Sissons P. Latency and reactivation of human cytomegalovirus. J Gen Virol. 2006;87:1763–79.PubMedCrossRef
11.
Barnabas RV, Celum C. Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions. Curr HIV Res. 2012;10:228–37.PubMedPubMedCentralCrossRef
12.
Gianella S, Morris SR, Anderson C, et al. Herpesviruses and HIV-1 drug resistance mutations influence the virologic and immunologic milieu of the male genital tract. AIDS. 2013;27:39–47.PubMedPubMedCentralCrossRef
13.
Lisco A, Munawwar A, Introini A, et al. Semen of HIV-1-infected individuals: local shedding of herpesviruses and reprogrammed cytokine network. J Infect Dis. 2012;205:97–105.PubMedPubMedCentralCrossRef
14.
Gianella S, Scheffler K, Mehta SR, et al. Seminal shedding of CMV and HIV transmission among men who have sex with Men. Int J Environ Res Publ Health. 2015;12:7585–92.CrossRef
15.
Mitchell C, Hitti J, Paul K, et al. Cervicovaginal shedding of HIV type 1 is related to genital tract inflammation independent of changes in vaginal microbiota. AIDS Res Hum Retrovir. 2011;27:35–9.PubMedPubMedCentralCrossRef
16.
Schoenfisch AL, Dollard SC, Amin M, et al. Cytomegalovirus (CMV) shedding is highly correlated with markers of immunosuppression in CMV-seropositive women. J Med Microbiol. 2011;60:768–74.PubMedCrossRef
17.
Mostad SB, Kreiss JK, Ryncarz AJ, et al. Cervical shedding of cytomegalovirus in human immunodeficiency virus type 1-infected women. J Med Virol. 1999;59:469–73.PubMedCrossRef
18.
Casper C, Krantz EM, Corey L, et al. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis. 2008;198:23–30.PubMedPubMedCentralCrossRef
19.
Hunt PW, Martin JN, Sinclair E, et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis. 2011;203:1474–83.PubMedPubMedCentralCrossRef
20.
Gianella S, Anderson CM, Vargas MV, et al. CMV DNA in semen and blood is associated with higher levels of proviral HIV DNA. J Infect Dis. 2012;207:898–902.PubMedPubMedCentralCrossRef
21.
Gianella S, Anderson C, Var SR, et al. Detectable CMVin PBMC Is Associated with Slower HIV DNA Decay during Suppressive ART. 22th Conference on Retroviruses and opportunistic infections (CROI). Seattle, 2015. Under Review.
22.
Reitter A, Buxmann H, Haberl AE, et al. Incidence of CMV co-infection in HIV-positive women and their neonates in a tertiary referral centre: a cohort study. Med Microbiol Immunol. 2015. doi:10.​1007/​s00430-015-0427-9.
23.
Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202:673–85.PubMedPubMedCentralCrossRef
24.
Li H, Margolick JB, Bream JH, et al. Heterogeneity of CD4+ and CD8+ T-cell responses to cytomegalovirus in HIV-infected and HIV-uninfected men who have sex with men. J Infect Dis. 2014;210:400–4.PubMedPubMedCentralCrossRef
25.
Stone SF, Price P, Khan N, Moss PA, French MA. HIV patients on antiretroviral therapy have high frequencies of CD8 T cells specific for Immediate Early protein-1 of cytomegalovirus. AIDS. 2005;19:555–62.PubMedCrossRef
26.
Naeger DM, Martin JN, Sinclair E, et al. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One. 2010;5:e8886.PubMedPubMedCentralCrossRef
27.•
Stern-Ginossar N, Weisburd B, Michalski A, et al. Decoding human cytomegalovirus. Science. 2012;338:1088–93. The results of this study revealed an unanticipated complexity to the HCMV coding capacity and illustrate the role of regulated changes in transcript start sites in generating this complexity. PubMedCrossRef
28.
Soderberg-Naucler C. Treatment of cytomegalovirus infections beyond acute disease to improve human health. Expert Rev Anti-Infect Ther. 2014;12:211–22.PubMedCrossRef
29.
Lisco A, Vanpouille C, Margolis L. War and peace between microbes: HIV-1 interactions with coinfecting viruses. Cell Host Microbe. 2009;6:403–8.PubMedCrossRef
30.
Almeida GD, Porada CD, St Jeor S, Ascensao JL. Human cytomegalovirus alters interleukin-6 production by endothelial cells. Blood. 1994;83:370–6.PubMed
31.
Suni MA, Ghanekar SA, Houck DW, et al. CD4(+)CD8(dim) T lymphocytes exhibit enhanced cytokine expression, proliferation and cytotoxic activity in response to HCMV and HIV-1 antigens. Eur J Immunol. 2001;31:2512–20.PubMedCrossRef
32.
Iwamoto GK, Monick MM, Clark BD, Auron PE, Stinski MF, Hunninghake GW. Modulation of interleukin 1 beta gene expression by the immediate early genes of human cytomegalovirus. J Clin Invest. 1990;85:1853–7.PubMedPubMedCentralCrossRef
33.
Saghafian-Hedengren S, Sohlberg E, Theorell J, et al. Epstein-Barr virus coinfection in children boosts cytomegalovirus-induced differentiation of natural killer cells. J Virol. 2013;87:13446–55.PubMedPubMedCentralCrossRef
34.
Fawaz LM, Sharif-Askari E, Menezes J. Up-regulation of NK cytotoxic activity via IL-15 induction by different viruses: a comparative study. J Immunol. 1999;163:4473–80.PubMed
35.
Overwijk WW, Schluns KS. Functions of gammaC cytokines in immune homeostasis: current and potential clinical applications. Clin Immunol. 2009;132:153–65.PubMedPubMedCentralCrossRef
36.
Chang WL, Baumgarth N, Yu D, Barry PA. Human cytomegalovirus-encoded interleukin-10 homolog inhibits maturation of dendritic cells and alters their functionality. J Virol. 2004;78:8720–31.PubMedPubMedCentralCrossRef
37.
Kotenko SV, Saccani S, Izotova LS, Mirochnitchenko OV, Pestka S. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci U S A. 2000;97:1695–700.PubMedPubMedCentralCrossRef
38.
Soderberg-Naucler C. Human cytomegalovirus persists in its host and attacks and avoids elimination by the immune system. Crit Rev Immunol. 2006;26:231–64.PubMedCrossRef
39.
Powers C, DeFilippis V, Malouli D, Fruh K. Cytomegalovirus immune evasion. Curr Top Microbiol Immunol. 2008;325:333–59.PubMed
40.
Dan J, Massanella M, Spina C, et al. Effect of cytomegalovirus and HIV transcription on CD57 and PD-1 T cell expression during suppressive ART. JAIDS. 2016. In press.
41.
Johnson DC, Hegde NR. Inhibition of the MHC class II antigen presentation pathway by human cytomegalovirus. Curr Top Microbiol Immunol. 2002;269:101–15.PubMed
42.
Shive CL, Mudd JC, Funderburg NT, et al. Inflammatory cytokines drive CD4+ T-cell cycling and impaired responsiveness to interleukin 7: implications for immune failure in HIV disease. J Infect Dis. 2014;210:619–29.PubMedPubMedCentralCrossRef
43.
Biancotto A, Grivel JC, Iglehart SJ, et al. Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood. 2007;109:4272–9.PubMedPubMedCentralCrossRef
44.
45.
Torti N, Walton SM, Brocker T, Rulicke T, Oxenius A. Non-hematopoietic cells in lymph nodes drive memory CD8 T cell inflation during murine cytomegalovirus infection. PLoS Pathog. 2011;7:e1002313.PubMedPubMedCentralCrossRef
46.
47.
Lang A, Brien JD, Nikolich-Zugich J. Inflation and long-term maintenance of CD8 T cells responding to a latent herpesvirus depend upon establishment of latency and presence of viral antigens. J Immunol. 2009;183:8077–87.PubMedPubMedCentralCrossRef
48.
Remmerswaal EB, Klarenbeek PL, Alves NL, et al. Clonal evolution of CD8+ T cell responses against latent viruses: relationship among phenotype, localization, and function. J Virol. 2015;89:568–80.PubMedPubMedCentralCrossRef
49.
Fletcher JM, Vukmanovic-Stejic M, Dunne PJ, et al. Cytomegalovirus-specific CD4+ T cells in healthy carriers are continuously driven to replicative exhaustion. J Immunol. 2005;175:8218–25.PubMedCrossRef
50.
Almanzar G, Schwaiger S, Jenewein B, et al. Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J Virol. 2005;79:3675–83.PubMedPubMedCentralCrossRef
51.
Cicin-Sain L, Brien JD, Uhrlaub JL, Drabig A, Marandu TF, Nikolich-Zugich J. Cytomegalovirus infection impairs immune responses and accentuates T-cell pool changes observed in mice with aging. PLoS Pathog. 2012;8:e1002849.PubMedPubMedCentralCrossRef
52.
Mekker A, Tchang VS, Haeberli L, Oxenius A, Trkola A, Karrer U. Immune senescence: relative contributions of age and cytomegalovirus infection. PLoS Pathog. 2012;8:e1002850.PubMedPubMedCentralCrossRef
53.
Smithey MJ, Li G, Venturi V, Davenport MP, Nikolich-Zugich J. Lifelong persistent viral infection alters the naive T cell pool, impairing CD8 T cell immunity in late life. J Immunol. 2012;189:5356–66.PubMedPubMedCentralCrossRef
54.
van Leeuwen EM, Koning JJ, Remmerswaal EB, van Baarle D, van Lier RA, ten Berge IJ. Differential usage of cellular niches by cytomegalovirus versus EBV- and influenza virus-specific CD8+ T cells. J Immunol. 2006;177:4998–5005.PubMedCrossRef
55.
Remmerswaal EB, Havenith SH, Idu MM, et al. Human virus-specific effector-type T cells accumulate in blood but not in lymph nodes. Blood. 2012;119:1702–12.PubMedCrossRef
56.
Arens R, Remmerswaal EB, Bosch JA, van Lier RA. 5(th) International Workshop on CMV and Immunosenescence—a shadow of cytomegalovirus infection on immunological memory. Eur J Immunol. 2015;45:954–7.PubMedCrossRef
57.
Sauce D, Larsen M, Fastenackels S, et al. Evidence of premature immune aging in patients thymectomized during early childhood. J Clin Invest. 2009;119:3070–8.PubMedPubMedCentralCrossRef
58.
Harris JM, Hazenberg MD, Poulin JF, et al. Multiparameter evaluation of human thymic function: interpretations and caveats. Clin Immunol. 2005;115:138–46.PubMedCrossRef
59.
Lichtner M, Cicconi P, Vita S, et al. Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. J Infect Dis. 2015;211:178–86.PubMedCrossRef
60.•
Brodin P, Jojic V, Gao T, et al. Variation in the human immune system is largely driven by non-heritable influences. Cell. 2015;160:37–47. By studying twins, this study found that non-heritable influences (inclusive CMV serostatus) explain much of the variation in immune measurements. PubMedPubMedCentralCrossRef
61.
Olsson J, Wikby A, Johansson B, Lofgren S, Nilsson BO, Ferguson FG. Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. Mech Ageing Dev. 2000;121:187–201.PubMedCrossRef
62.
Strindhall J, Nilsson BO, Lofgren S, et al. No immune risk profile among individuals who reach 100 years of age: findings from the Swedish NONA immune longitudinal study. Exp Gerontol. 2007;42:753–61.PubMedCrossRef
63.
Dowd JB, Aiello AE, Alley DE. Socioeconomic disparities in the seroprevalence of cytomegalovirus infection in the US population: NHANES III. Epidemiol Infect. 2009;137:58–65.PubMedPubMedCentralCrossRef
64.
Simanek AM, Dowd JB, Pawelec G, Melzer D, Dutta A, Aiello AE. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS One. 2011;6:e16103.PubMedPubMedCentralCrossRef
65.
Strandberg TE, Pitkala KH, Tilvis RS. Cytomegalovirus antibody level and mortality among community-dwelling older adults with stable cardiovascular disease. JAMA. 2009;301:380–2.PubMedCrossRef
66.
Parrinello CM, Sinclair E, Landay AL, et al. Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women. J Infect Dis. 2012;205:1788–96.PubMedPubMedCentralCrossRef
67.
Gianella S, Morris SR, Tatro E, et al. Virologic Correlates of Anti-CMV IgG Levels in HIV-1 Infected Men. J Infect Dis. 2014;209(3):452–6.
68.
Hadrup SR, Strindhall J, Kollgaard T, et al. Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. J Immunol. 2006;176:2645–53.PubMedCrossRef
69.•
Furman D, Jojic V, Sharma S, et al. Cytomegalovirus infection enhances the immune response to influenza. Sci Transl Med. 2015;7:281ra43. This study found that latent CMV infection could be beneficial in that it enhanced the development of an influenza vaccine-specific antibody response in young, but not aged, individuals. PubMedPubMedCentralCrossRef
70.
Skolnik PR, Kosloff BR, Hirsch MS. Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus. J Infect Dis. 1988;157:508–14.PubMedCrossRef
71.
Yuan R, Bohan C, Shiao FC, Robinson R, Kaplan HJ, Srinivasan A. Activation of HIV LTR-directed expression: analysis with pseudorabies virus immediate early gene. Virology. 1989;172:92–9.PubMedCrossRef
72.
73.
Johnson EL, Howard CL, Thurman J, Pontiff K, Johnson ES, Chakraborty R. CMV upregulates expression of CCR5 in central memory TCM cord blood mononuclear cells which may facilitate in utero HIV-1 transmission. J Infect Dis. 2015;211(2):187–96.
74.
75.
Gianella S, Massanella M, Richman DD, et al. Cytomegalovirus replication in semen is associated with higher levels of proviral HIV DNA and CD4+ T cell activation during antiretroviral treatment. J Virol. 2014;88:7818–27.PubMedPubMedCentralCrossRef
76.
77.
Gianella S, Strain MC, Rought SE, et al. Associations between virologic and immunologic dynamics in blood and in the male genital tract. J Virol. 2012;86:1307–15.PubMedPubMedCentralCrossRef
78.
Kim HN, Wang J, Hughes J, et al. Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection. J Infect Dis. 2010;202:734–8.PubMedPubMedCentralCrossRef
79.
Gianella S, Smith DM, Vargas MV, et al. Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men. Clin Infect Dis. 2013;57:441–7.PubMedPubMedCentralCrossRef
80.
Webster A, Lee CA, Cook DG, et al. Cytomegalovirus infection and progression towards AIDS in haemophiliacs with human immunodeficiency virus infection. Lancet. 1989;2:63–6.PubMedCrossRef
81.
Detels R, Leach CT, Hennessey K, et al. Persistent cytomegalovirus infection of semen increases risk of AIDS. J Infect Dis. 1994;169:766–8.PubMedCrossRef
82.
Deayton J, Mocroft A, Wilson P, Emery VC, Johnson MA, Griffiths PD. Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy. AIDS. 1999;13:1203–6.PubMedCrossRef
83.
Freeman ML, Mudd JC, Shive CL, et al. M CD8 T cell expansion and inflammation linked to CMV co-infection in ART-treated HIV infection. Clin Infect Dis. 2016;62(3):392–6.
84.
Barrett L, Stapleton SN, Fudge NJ, Grant MD. Immune resilience in HIV-infected individuals seronegative for cytomegalovirus. AIDS. 2014;28:2045–9.PubMedCrossRef
85.
Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014;10:e1004078.PubMedPubMedCentralCrossRef
86.
87.
88.
Khan N, Shariff N, Cobbold M, et al. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol. 2002;169:1984–92.PubMedCrossRef
89.
Khan N, Cobbold M, Cummerson J, Moss PA. Persistent viral infection in humans can drive high frequency low-affinity T-cell expansions. Immunology. 2010;131:537–48.PubMedPubMedCentralCrossRef
90.
Ouyang Q, Wagner WM, Zheng W, Wikby A, Remarque EJ, Pawelec G. Dysfunctional CMV-specific CD8(+) T cells accumulate in the elderly. Exp Gerontol. 2004;39:607–13.PubMedCrossRef
91.
Chidrawar S, Khan N, Wei W, et al. Cytomegalovirus-seropositivity has a profound influence on the magnitude of major lymphoid subsets within healthy individuals. Clin Exp Immunol. 2009;155:423–32.PubMedPubMedCentralCrossRef
92.
93.
Letendre S, Bharti A, Perez-Valero I, et al. Higher Anti-CMV IgG Concentrations are Associated with Worse Neurocognitive Functioning in People Living with HIV Disease. Under review 2013.
94.
Bruning JH, Persoons M, Lemstrom K, Stals FS, De Clercq E, Bruggeman CA. Enhancement of transplantation-associated atherosclerosis by CMV, which can be prevented by antiviral therapy in the form of HPMPC. Trans Int Off J Eur Soc Organ Trans. 1994;7 Suppl 1:S365–70.
95.
Watkins RR, Lemonovich TL, Razonable RR. Immune response to CMV in solid organ transplant recipients: current concepts and future directions. Expert Rev Clin Immunol. 2012;8:383–93.PubMedCrossRef
96.
Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS. 2006;20:2275–83.PubMedCrossRef
97.
Barrett L, Fowke KR, Grant MD. Cytomegalovirus, aging, and HIV: a perfect storm. AIDS Rev. 2012;14:159–67.PubMed
98.
Bolovan-Fritts CA, Spector SA. Endothelial damage from cytomegalovirus-specific host immune response can be prevented by targeted disruption of fractalkine-CX3CR1 interaction. Blood. 2008;111:175–82.PubMedPubMedCentralCrossRef
99.
Bolovan-Fritts CA, Trout RN, Spector SA. High T-cell response to human cytomegalovirus induces chemokine-mediated endothelial cell damage. Blood. 2007;110:1857–63.PubMedPubMedCentralCrossRef
100.
Combadiere B, Faure S, Autran B, Debre P, Combadiere C. The chemokine receptor CX3CR1 controls homing and anti-viral potencies of CD8 effector-memory T lymphocytes in HIV-infected patients. AIDS. 2003;17:1279–90.PubMedCrossRef
101.
Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013;369:1227–36.PubMedCrossRef
102.
103.
Jones TR, Sun L. Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains. J Virol. 1997;71:2970–9.PubMedPubMedCentral
104.
Jones TR, Wiertz EJ, Sun L, Fish KN, Nelson JA, Ploegh HL. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci U S A. 1996;93:11327–33.PubMedPubMedCentralCrossRef
105.
Ahn K, Gruhler A, Galocha B, et al. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity. 1997;6:613–21.PubMedCrossRef
106.
Lehner PJ, Karttunen JT, Wilkinson GW, Cresswell P. The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. Proc Natl Acad Sci U S A. 1997;94:6904–9.PubMedPubMedCentralCrossRef
107.
Jones TR, Hanson LK, Sun L, Slater JS, Stenberg RM, Campbell AE. Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains. J Virol. 1995;69:4830–41.PubMedPubMedCentral
108.
Park B, Spooner E, Houser BL, Strominger JL, Ploegh HL. The HCMV membrane glycoprotein US10 selectively targets HLA-G for degradation. J Exp Med. 2010;207:2033–41.PubMedPubMedCentralCrossRef
109.
Tomazin R, Boname J, Hegde NR, et al. Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells. Nat Med. 1999;5:1039–43.PubMedCrossRef
110.
Hegde NR, Tomazin RA, Wisner TW, et al. Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation. J Virol. 2002;76:10929–41.PubMedPubMedCentralCrossRef
111.
Miller DM, Zhang Y, Rahill BM, Waldman WJ, Sedmak DD. Human cytomegalovirus inhibits IFN-alpha-stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN-alpha signal transduction. J Immunol. 1999;162:6107–13.PubMed
112.
Paulus C, Krauss S, Nevels M. A human cytomegalovirus antagonist of type I IFN-dependent signal transducer and activator of transcription signaling. Proc Natl Acad Sci U S A. 2006;103:3840–5.PubMedPubMedCentralCrossRef
113.
Taylor RT, Bresnahan WA. Human cytomegalovirus IE86 attenuates virus- and tumor necrosis factor alpha-induced NFkappaB-dependent gene expression. J Virol. 2006;80:10763–71.PubMedPubMedCentralCrossRef
114.
Beck S, Barrell BG. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature. 1988;331:269–72.PubMedCrossRef
115.
Cosman D, Mullberg J, Sutherland CL, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14:123–33.PubMedCrossRef
116.
Chalupny NJ, Rein-Weston A, Dosch S, Cosman D. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem Biophys Res Commun. 2006;346:175–81.PubMedCrossRef
117.
118.
Tomasec P, Wang EC, Davison AJ, et al. Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nat Immunol. 2005;6:181–8.PubMedPubMedCentralCrossRef
119.
Arnon TI, Achdout H, Levi O, et al. Inhibition of the NKp30 activating receptor by pp 65 of human cytomegalovirus. Nat Immunol. 2005;6:515–23.PubMedCrossRef
120.
Fielding CA, Aicheler R, Stanton RJ, et al. Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation. PLoS Pathog. 2014;10:e1004058.PubMedPubMedCentralCrossRef
121.
Wyrwicz LS, Rychlewski L. Cytomegalovirus immediate early gene UL37 encodes a novel MHC-like protein. Acta Biochim Pol. 2008;55:67–73.PubMed
122.
Knoblach T, Grandel B, Seiler J, Nevels M, Paulus C. Human cytomegalovirus IE1 protein elicits a type II interferon-like host cell response that depends on activated STAT1 but not interferon-gamma. PLoS Pathog. 2011;7:e1002016.PubMedPubMedCentralCrossRef
123.
124.
125.
Neote K, DiGregorio D, Mak JY, Horuk R, Schall TJ. Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell. 1993;72:415–25.PubMedCrossRef
126.
Benedict CA, Butrovich KD, Lurain NS, et al. Cutting edge: a novel viral TNF receptor superfamily member in virulent strains of human cytomegalovirus. J Immunol. 1999;162:6967–70.PubMed
127.
128.
Chiou SH, Yang YP, Lin JC, et al. The immediate early 2 protein of human cytomegalovirus (HCMV) mediates the apoptotic control in HCMV retinitis through up-regulation of the cellular FLICE-inhibitory protein expression. J Immunol. 2006;177:6199–206.PubMedCrossRef
129.
Skaletskaya A, Bartle LM, Chittenden T, McCormick AL, Mocarski ES, Goldmacher VS. A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation. Proc Natl Acad Sci U S A. 2001;98:7829–34.PubMedPubMedCentralCrossRef
130.
Goldmacher VS, Bartle LM, Skaletskaya A, et al. A cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally unrelated to Bcl-2. Proc Natl Acad Sci U S A. 1999;96:12536–41.PubMedPubMedCentralCrossRef
131.
Smith W, Tomasec P, Aicheler R, et al. Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses. Cell Host Microbe. 2013;13:324–35.PubMedPubMedCentralCrossRef
132.
Reeves MB, Davies AA, McSharry BP, Wilkinson GW, Sinclair JH. Complex I binding by a virally encoded RNA regulates mitochondria-induced cell death. Science. 2007;316:1345–8.PubMedCrossRef
133.
Iwamoto GK, Konicek SA. Cytomegalovirus immediate early genes upregulate interleukin-6 gene expression. J Investig Med. 1997;45:175–82.PubMed
134.
Smith PD, Saini SS, Raffeld M, Manischewitz JF, Wahl SM. Cytomegalovirus induction of tumor necrosis factor-alpha by human monocytes and mucosal macrophages. J Clin Invest. 1992;90:1642–8.PubMedPubMedCentralCrossRef
Metadata
Title
Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection
Authors
Michael L. Freeman
Michael M. Lederman
Sara Gianella
Publication date
01-02-2016
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 1/2016
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-016-0297-9

Other articles of this Issue 1/2016

Current HIV/AIDS Reports 1/2016 Go to the issue

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Post-Treatment Controllers: Role in HIV “Cure” Research

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Recent Insights Into Cardiovascular Disease (CVD) Risk Among HIV-Infected Adults

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Novel Imaging Methods for Analysis of Tissue Resident Cells in HIV/SIV

The Science of Prevention (JD Stekler and J Baeten, Section Editors)

Modeling and Cost-Effectiveness in HIV Prevention

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Friend or Foe: Innate Sensing of HIV in the Female Reproductive Tract

HIV Pathogenesis and Treatment (AL Landay, Section Editor)

Broadly Neutralizing Antibodies for HIV Eradication
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits